Advertisement

Topics

Oppenheimer & Co. Inc. Company Profile

13:37 EST 23rd November 2017 | BioPortfolio


News Articles [20 Associated News Articles listed on BioPortfolio]

Oppenheimer-Analysten starten Coberage der Biogen-Aktie! - Aktienanalyse

New York - Biogen-Aktienanalyse von Analyst Jay Olson von Oppenheimer: Laut einer Aktienanalyse äußert Analyst Jay Olson vom Investmenthaus Oppenheimer im Rahmen einer Ersteinschätzung die Erwartun...

Oppenheimer belässt Microsoft auf 'Outperform'

Die amerikanische Investmentbank Oppenheimer hat die Einstufung für die Aktien des Software-Konzerns Microsoft auf "Outperform" mit einem Kursziel von 80 US-Dollar belassen. Dies geht aus einer am...

Oppenheimer hebt Ziel für Wal-Mart auf 100 Dollar - 'Outperform'

Die amerikanische Investmentbank Oppenheimer hat das Kursziel für Wal-Mart von 90 auf 100 US-Dollar angehoben und die Einstufung auf "Outperform" belassen. Dies geht aus einer am Mittwoch veröffen.....

Oppenheimer startet Wal-Mart mit 'Outperform' - Ziel 90 US-Dollar

Die amerikanische Investmentbank Oppenheimer hat Wal-Mart mit "Outperform" und einem Kursziel von 90 US-Dollar in die Bewertung aufgenommen. Dies geht aus einer am Dienstag veröffentlichten Studie...

Apple-Aktie: Leaks trüben die Begeisterung empfindlich! - Aktienanalyse

New York - Apple-Aktienanalyse des Analysten Andrew Uerkwitz von Oppenheimer: Im Rahmen einer Aktienanalyse äußert Analyst Andrew Uerkwitz vom Investmenthaus Oppenheimer in Bezug auf die Aktien von....

Downgrade für Intercept Pharmaceuticals-Aktie! - Aktienanalyse

New York - Intercept Pharmaceuticals-Aktienanalyse des Analysten Jay Olson von Oppenheimer: Im Rahmen einer Aktienanalyse rechnet Jay Olson, Analyst beim Investmenthaus Oppenheimer, nur noch mit ei...

Teva, Mylan Seen to Stay on M&A Sidelines

Teva is 'in no shape' to be making acquisitions while Mylan is 'still pretty leveraged,' says Oppenheimer analyst Derek Archila. Teva Pharmaceutical Industries Ltd. and Mylan NV will p...

TEVA Pharmaceuticals-Aktie: Mylan-Nachricht ist keine Überraschung! - Aktienanalyse

New York - TEVA Pharmaceuticals-Aktienanalyse des Analysten Derek Archila von Oppenheimer: Derek Archila, Aktienanalyst von Oppenheimer, äußert im Rahmen einer aktuellen Aktienanalyse zu den Aktien....

Drugs and Medications [0 Results]

None

PubMed Articles [12 Associated PubMed Articles listed on BioPortfolio]

Liberation of H2 from (o-C6H4Me)3P-H((+)) + ((-))H-B(p-C6F4H)3 ion-pair: A transition-state in the minimum energy path versus the transient species in Born-Oppenheimer molecular dynamics.

Using Born-Oppenheimer molecular dynamics (BOMD) with density functional theory, transition-state (TS) calculations, and the quantitative energy decomposition analysis (EDA), we examined the mechanism...

Efficient, "on-the-fly", Born-Oppenheimer and Car-Parrinello-type dynamics with coupled cluster (CCSD) accuracy through fragment based electronic structure.

We recently developed two fragment based ab initio molecular dynamics methods and in this publication we have demonstrated both approaches by constructing efficient classical trajectories in agreement...

Constructive and Destructive Interferences in Nonadiabatic Tunneling via Conical Intersections.

As a manifestation of the molecular Ahanorov-Bohm effect, tunneling-facilitated dissociation under a conical intersection (CI) requires the inclusion of the geometric phase (GP) in order to ensure a s...

Fully quantum description of the Zundel ion: combining variational quantum Monte Carlo with path integral Langevin dynamics.

We introduce a novel approach for a fully quantum description of coupled electron-ion systems from first principles. It combines the variational quantum Monte Carlo solution of the electronic part wit...

Nonadiabatic Kohn Anomaly in Heavily Boron-Doped Diamond.

We report evidence of a nonadiabatic Kohn anomaly in boron-doped diamond, using a joint theoretical and experimental analysis of the phonon dispersion relations. We demonstrate that standard calculati...

Clinical Trials [0 Results]

None

More Information about "Oppenheimer & Co. Inc." on BioPortfolio

We have published hundreds of Oppenheimer & Co. Inc. news stories on BioPortfolio along with dozens of Oppenheimer & Co. Inc. Clinical Trials and PubMed Articles about Oppenheimer & Co. Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oppenheimer & Co. Inc. Companies in our database. You can also find out about relevant Oppenheimer & Co. Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record